A Trial Investigating the Effect of Oral Semaglutide Compared With Placebo on Postprandial Glucose and Triglyceride Metabolism, Energy Intake, Appetite Sensations and Gastric Emptying in Subjects With Type 2 Diabetes
Latest Information Update: 23 Jul 2021
At a glance
- Drugs Semaglutide (Primary) ; Paracetamol
- Indications Type 2 diabetes mellitus
- Focus Pharmacokinetics
- Sponsors Novo Nordisk
- 01 Jul 2021 Primary endpoint has been met. (area under the glucose 05-h curve (AUC05h) after the standard breakfast), as per Results published in the Diabetes, Obesity and Metabolism
- 01 Jul 2021 Results assessing the effects of oral semaglutide on postprandial glucose and lipid metabolism, and gastric emptying, in subjects with type 2 diabetes, published in the Diabetes, Obesity and Metabolism
- 30 Oct 2018 Status changed from active, no longer recruiting to completed.